Insider buying last 90 days
No open-market insider purchases were filed for SBRA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SBRA insider filing, plotted on the chart in Gekko.Open SBRA in Gekko
Sabra Health Care REIT (SBRA) Stock Analysis & Forecast
Sep 28 close
$19.82−0.03 (−0.2%)
Gekko Brief
AI summarySabra Healthcare REIT receives a "Moderate Buy" rating from Wall Street brokerages this week, with analysts split between buy and hold recommendations and an average 12-month price target of $22.23, above its recent price of $19.77. Alongside the rating news, filings show shifting institutional positions, including a reduction by Squarepoint Ops LLC.
Shares close at $19.82, down 0.2%, sitting between the 50-day average of $20.70 and the 200-day average of $19.94, a mixed trend picture. The GekkoIndex reads 65.1, placing SBRA in the Accumulation zone, while the price stands 35.1% below Gekko Fair Value of $30.54.
The next earnings report is scheduled for 4 November 2026, 36 days out and beyond a typical 20-trading-day hold. At the last report, on 12 February 2026, Sabra posted EPS of $0.38 against an estimate of $0.17, with an average absolute reaction of 2.4% across recent quarters. No insider, Congress, or unusual options activity appears in the current window. Seasonality over the next 20 trading days has averaged 0.4% across 5 years, rising in 2 of them. Analyst coverage currently stands at 11 firms, with 5 rating the stock a buy and 6 a hold, and a consensus target of $22.79 implying 15% upside. The gap to Gekko Fair Value bears watching alongside the approaching earnings date.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Sabra Health Care REIT price vs fair value
Close $19.82200-day averageGekko Fair Value $30.54
Sabra Health Care REIT quick facts
- Market cap
- $5.00B
- P/E ratio
- 76.4
- Forward P/E
- 32.2
- EPS, TTM
- $0.26
- Revenue, TTM
- $863.8M
- Profit margin
- 7.6%
- Dividend yield
- 6.07%
- Beta
- 0.64
- Volume
- 1.86M avg 2.40M
- 1-year return
- +6.2%
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.3%
- 50-day average
- $20.70
- 200-day average
- $19.94
- Next earnings
- Nov 4
- Shares outstanding
- 255.5M
Sabra Health Care REIT swing-trade checklist
Sabra Health Care REIT scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $19.82 sits between the 50-day ($20.70) and 200-day ($19.94) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.1, Accumulation
Reading 65.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
35.1% below
Price is 35.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.4% on average
From this point in the calendar, the next 20 trading days averaged +0.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Sabra Health Care REIT stock chart and price history
Sabra Health Care REIT closed at $19.82 on Sep 28, 2026, +6.2% over the past year, inside a 52-week range of $17.17 to $22.77.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.3%
- 3 months
- +1.5%
- 6 months
- +1.1%
- 1 year
- +6.2%
The full SBRA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SBRA in Gekko
Follow Sabra Health Care REIT through every session
Put SBRA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SBRA in GekkoFree for 7 days. No credit card required.
About Sabra Health Care REIT
Sabra Health Care REIT is engaged in the acquisition, financing, and ownership of real estate property. Its core activity involves building up holdings of property assets through purchase and funding arrangements, positioning the company within the real estate investment space. This work of acquiring and holding property is the primary way the company is known.
The company generates its earnings by owning and financing the real estate it acquires, with its business structured around the management of these property holdings. Its operations center on the cycle of obtaining properties, arranging the financing needed to support that ownership, and retaining these assets over time.
Sabra Health Care REIT was founded on May 10, 2010, and its headquarters are located in Tustin, California. The company's shares trade under the ticker SBRA.
- Sector
- Finance
- Website
- sabrahealth.com
Sabra Health Care REIT GekkoIndex: the smart money zone
Sabra Health Care REIT’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.1, in the Accumulation zone, down 2.7 points over five sessions.
65.1Accumulation
Down 2.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +1.0% | +4.5% | ||
| Accumulation (current zone) | 143 | +0.7% | +3.2% | ||
| Neutral | 428 | +0.2% | +0.9% | ||
| Distribution | 35 | −0.5% | −1.4% | ||
| Selling | 0 | Not available | |||
Average SBRA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SBRA price, zone by zone.Track SBRA in Gekko
Is Sabra Health Care REIT stock overvalued? Gekko Fair Value
Sabra Health Care REIT trades 35.1% below Gekko Fair Value of $30.54, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Sabra Health Care REIT shares are worth, recalculated every trading day.
$30.54
Gekko Fair Value, Sep 26, 2026
35.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SBRA in Gekko
Sabra Health Care REIT insider and Congress trading
No open-market insider purchases were filed for Sabra Health Care REIT, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SBRA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SBRA, plotted on the chart in Gekko.Open SBRA in Gekko
Buybacks
Sabra Health Care REIT has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $8.25M
- As a share of market cap
- 0.16%
From company filings.
Sabra Health Care REIT earnings: next date and track record
Sabra Health Care REIT reports on Nov 4, 2026 (36 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
36 days away
- EPS estimate
- $0.17
- Revenue estimate
- $234.0M
3 of 8reports beat the EPS estimate
±2.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 12, 2026 AI summary
- What they said
- Sabra reported a strong fourth quarter 2025 driven by its SHOP (senior housing operating) portfolio. Management highlighted sequential and year-over-year revenue, occupancy, and RevPAR gains, with particular strength in Canada. The company invested heavily in SHOP assets (~$150 million in the quarter; ~$450 million year-to-date) and has ~$240 million of awarded transactions (predominantly SHOP) with most expected to close in Q1/early Q2 2026. Same-store managed senior housing revenue grew 6.4% YoY and occupancy improved materially (up 160 bps YoY to 87.9% overall; Canadian same-store occupancy 94.2%). Management reported normalized FFO/AFFO metrics for the quarter and introduced full-year 2026 guidance (including net income and FFO ranges). The transition facilities (Holiday portfolio) lag but are expected to recover and add to SHOP NOI growth. Management discussed capital allocation, ongoing deal flow, modest cap-rate compression but continued ability to find assets in the mid-to-high single-digit cap-rate range, and their operational experience and infrastructure as a differentiator. Regulatory trends in Medicaid/Medicare were discussed as normalizing after pandemic-driven peaks. Overall tone from management was confident and constructive, with some acknowledged uncertainties (loan maturity later in 2026, Holiday transitions, and industry competition).
- Guidance
- Company provided full-year 2026 guidance: net income $0.60 to $0.64 per diluted share; FFO and normalized FFO approx. $1.49 to $1.50 per share; management earlier referenced guidance implying ~4.9% to 5.4% growth at the midpoint for normalized FFO and normalized AFFO. (Guidance for some metrics was partially truncated in the transcript; the company emphasized normalized FFO/AFFO growth in the ~mid-single-digit range.)
- Risks flagged
- Risks mentioned or implied: uncertainty around the RCA loan maturing at year-end (though tenant is servicing debt); Holiday transition assets lagging and timeline for their recovery is uncertain; competitive pressure and cap-rate compression as more investors/REITs/private equity enter SHOP; expected normalization (reduction) of Medicaid and Medicare rate increases toward historical averages, which may be a headwind versus recent outsized increases; general macro/interest-rate environment and execution risk as portfolio scales.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 12, 2026 | $0.38 est $0.17 | $211.9M est $198.0M | +2.9% |
| Oct 29, 2025 | $0.17 est $0.18 | $190.0M est $202.0M | −1.6% |
| Aug 4, 2025 | $0.38 est $0.37 | $189.2M est $187.5M | −0.6% |
| May 6, 2025 | $0.17 est $0.14 | $183.5M est $182.5M | +4.6% |
| Feb 25, 2025 | $0.17 est $0.17 | — | +3.2% |
| Oct 31, 2024 | $0.13 est $0.16 | $178.0M est $175.6M | −4.8% |
| Aug 7, 2024 | $0.10 est $0.15 | $178.5M est $166.0M | −0.1% |
| May 8, 2024 | $0.11 est $0.14 | $172.2M est $162.0M | −1.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Sabra Health Care REIT stock forecast and analyst price targets
Analysts’ average 12-month price target for Sabra Health Care REIT is $22.79, +15.0% from the last close, from 11 firms rating the stock in the last 90 days.
$22.79consensus 12-month target, +15.0% from the last close
Now $19.82Avg $22.79
Low $21High $25
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 1 | Wells Fargo | $23 | +16.0% |
| Aug 31 | Mizuho Securities | $21 | +6.0% |
| Aug 31 | Barclays | $23 | +16.0% |
| Aug 21 | UBS | $21 | +6.0% |
| Aug 17 | Bank of America Securities | — | — |
+3.2%average 20-day move after past Accumulation readings
+0.4%average move over the next 20 trading days in the last 5 years
±1.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Sabra Health Care REIT seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Sabra Health Care REIT averaged +0.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.5% | 1 of 5 |
| Next 10 trading days | −1.3% | 2 of 5 |
| Next 15 trading days | +0.8% | 3 of 5 |
| Next 20 trading days | +0.4% | 2 of 5 |
| Next 30 trading days | +2.5% | 4 of 5 |
For scale, SBRA’s typical 20-trading-day move in either direction is about 4.3%.
Sabra Health Care REIT market cap and key statistics
Sabra Health Care REIT’s market cap is $5.00B, with a P/E ratio of 76.4 and revenue of $863.8M over the last twelve months.
Valuation
- Market cap
- $5.00B
- P/E ratio
- 76.4
- Forward P/E
- 32.2
- EPS, TTM
- $0.26
- Gekko Fair Value
- $30.54
Trading
- Volume
- 1.86M
- Avg volume, 20 days
- 2.40M
- 52-week high
- $22.77
- 52-week low
- $17.17
- Shares outstanding
- 255.5M
Financials
- Revenue, TTM
- $863.8M
- Profit margin
- 7.6%
- Return on equity
- 2.4%
- Quarterly earnings growth, YoY
- −5.6%
Risk and income
- Beta
- 0.64
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.3%
- Dividend yield
- 6.07%
Sabra Health Care REIT stock news this week
Coverage of Sabra Health Care REIT this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Stock Rated "Moderate Buy" by Wall Street BrokeragesMarketBeat, Sep 25
- Sabra Healthcare REIT, Inc. $SBRA Stock Sold by Squarepoint Ops LLCMarketBeat, Sep 25
- Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Stock Rated “Moderate Buy” by Wall Street BrokeragesDefense World, Sep 25
- NewEdge Advisors LLC Has $1.39 Million Position in Sabra Healthcare REIT, Inc. $SBRAMarketBeat, Sep 21
- Tidal Investments LLC Has $741,000 Stock Holdings in Sabra Healthcare REIT, Inc. $SBRADefense World, Sep 21
Sabra Health Care REIT stock FAQ
What is Sabra Health Care REIT’s market cap?
Sabra Health Care REIT’s market cap is $5.00B at the Sep 28, 2026 close of $19.82, with 255.5M shares outstanding. The shares trade on a P/E ratio of 76.4.
What is the Sabra Health Care REIT stock forecast?
The consensus analyst 12-month price target for Sabra Health Care REIT is $22.79, +15.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 5 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Sabra Health Care REIT stock overvalued or undervalued?
On Gekko’s estimate Sabra Health Care REIT is undervalued: the Sep 28, 2026 close of $19.82 is 35.1% below Gekko Fair Value of $30.54. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Sabra Health Care REIT report earnings next?
Sabra Health Care REIT is expected to report on Nov 4, 2026 (36 days away). Analysts expect earnings of $0.17 per share on revenue of $234.0M. Sabra Health Care REIT beat the earnings estimate in 3 of its last 8 reports, moving 2.4% on average across the report.
What is Sabra Health Care REIT’s 52-week high and low?
Sabra Health Care REIT’s 52-week high is $22.77 and its 52-week low is $17.17; it closed at $19.82 on Sep 28, 2026, +6.2% over the past year.
Is Sabra Health Care REIT stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Sabra Health Care REIT the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.